Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9747326 | 1.00 | NPC1 (0.48) | NPC1RAB9AL3MBTL1P2RX4PTGDR2 | |
| SCHEMBL9750210 | 0.88 | NPC1 (0.50) | NPC1RAB9AL3MBTL1P2RX4PTGDR2 | |
| SCHEMBL8272822 | 0.84 | NPC1 (0.51) | NPC1RAB9AL3MBTL1P2RX4PTGDR2 | |
| SCHEMBL9235569 | 0.84 | NPC1 (0.44) | NPC1RAB9AL3MBTL1PTGDR2ACE | |
| SCHEMBL9964900 | 0.84 | NPC1 (0.44) | NPC1RAB9AL3MBTL1PTGDR2ACE | |
| SCHEMBL9964901 | 0.83 | NPC1 (0.47) | NPC1RAB9AL3MBTL1P2RX4PTGDR2 | |
| SCHEMBL9092066 | 0.83 | NPC1 (0.47) | NPC1RAB9AL3MBTL1P2RX4PTGDR2 | |
| SCHEMBL9930255 | 0.82 | NOTUM (0.43) | ACE | |
| SCHEMBL13429569 | 0.80 | SYK (0.50) | NPC1RAB9AL3MBTL1PTGDR2ACE | |
| SCHEMBL10646920 | 0.78 | NPC1 (0.52) | NPC1RAB9AL3MBTL1P2RX4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | IDO1, IDO2, INMT | NPC1 1168/4885RAB9A 1349/4885L3MBTL1 3059/4885 |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | NPC1 515/4885RAB9A 1343/4885L3MBTL1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.